|Description||The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonary hypertension.|
|Synonyms||T-0201 Sodium; T0201 Sodium; T 0201 Sodium; N-(6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)-5-(p-tolyl)pyrimidin-4-yl)-4-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide sodium salt|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
Sitaxentan sodium inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.69 nM and a pA2 of 8.0.
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.
Endothelin 3 (human, rat)
Endothelin 3 is a ligand of the endothelin (ET) receptors and a potent vasoconstrictor. Endothelin 3 increases blood pressure in spontaneously hypertensive and ...
Sarafotoxin S6c is a highly selective ETB endothelin receptor agonist (Ki = 0.29 and 28000 nM at ETB and ETA receptors, respectively).
Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.
Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.
The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...